SLC5A2 and venous thromboembolism: In the meta‐analysis of RCTs there was no association between SGLT2 inhibitor use and the risk of venous thromboembolism including deep vein thromboses and pulmonary emboli (relative risk 0.98 [95% CI, 0.75‐1.28]), but results from observational studies have been mixed.29, 30, 31